- Home
- GNLX vs VTGN Comparison
GNLX vs VTGN Comparison
Compare GNLX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | VTGN |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 28.8M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNLX | VTGN |
|---|---|---|
| Price | $2.60 | $0.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $19.75 | $0.90 |
| AVG Volume (30 Days) | 377.3K | ★ 1.2M |
| Earning Date | 11-05-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $721,000.00 |
| Revenue This Year | N/A | $87.21 |
| Revenue Next Year | N/A | $256.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $0.54 |
| 52 Week High | $8.54 | $5.14 |
Technical Indicators
Market Signals| Indicator | GNLX | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 30.60 | 25.10 |
| Support Level | $2.61 | $0.54 |
| Resistance Level | $2.97 | $0.60 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 18.04 | 8.20 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.